Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 2;9(6):e97929.
doi: 10.1371/journal.pone.0097929. eCollection 2014.

Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria

Affiliations

Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria

Alexander Pretsch et al. PLoS One. .

Abstract

Acne vulgaris is the most common skin disease, causing significant psychosocial problems such as anxiety and depression similar to a chronic illness for those afflicted. Currently, obtainable agents for acne treatment have limited use. Thus, development of novel agents to treat this disease is a high medical need. The anaerobic bacterium Propionibacterium acnes has been implicated in the inflammatory phase of acne vulgaris by activating pro-inflammatory mediators such as the interleukin-8 (IL-8) via the NF-κB and MAPK pathways. Talaromyces wortmannii is an endophytic fungus, which is known to produce high bioactive natural compounds. We hypothesize that compound C but also the crude extract from T. wortmannii may possess both antibacterial activity especially against P. acnes and also anti-inflammatory properties by inhibiting TNF-α-induced ICAM-1 expression and P. acnes-induced IL-8 release. Treatment of keratinocytes (HaCaT) with P. acnes significantly increased NF-κB and activator protein-1 (AP-1) activation, as well as IL-8 release. Compound C inhibited P. acnes-mediated activation of NF-κB and AP-1 by inhibiting IκB degradation and the phosphorylation of ERK and JNK MAP kinases, and IL-8 release in a dose-dependent manner. Based on these results, compound C has effective antimicrobial activity against P. acnes and anti-inflammatory activity, and we suggest that this substance or the crude extract are alternative treatments for antibiotic/anti-inflammatory therapy for acne vulgaris.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: SeaLife Pharma GmbH holds the patent for the Anthracene derivatives (“Neue Tetrahydroanthracenon-Derivate”; WO 2010135758 A1; compound AA ´) isolated from T. wortmannii. A. Pretsch, P. Proksch, and A. Debbab are the inventors of the patent and SeaLife Pharma GmbH is the patent holder. In the next two years, SeaLife GmbH plans to market and commercialize the T. wortmannii extract as a cosmetic product. A. Pretsch (Head of Microbiology and CEO), M. Nagl (Head of Chemistry), K. Schwendinger (Master Student), B. Kreiseder (Junior Scientist), M. Wiederstein (Junior Scientist), D. Pretsch (Junior Scientist), D. Zinssmeister (Master Student), M. Genov (Senior Scientist), R. Hollaus (Junior Scientist), and C. Wiesner (CSO) are all employed at SeaLife Pharma GmbH. Beside the product above, SeaLife Pharma GmbH is developing (pre-clinical studies) an anti-infective Anthraquinone-Derivative (patent in preparation) for the treatment of MRSA. Up to now, SeaLife Pharma has no products on the market. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Analytical HPLC/MS profiles.
(A) HPLC/MS profile of the crude extract of T. wortmannii isolated with EtOAc. (B) Chromatogram after straight phase and sephadex-G50 separation.
Figure 2
Figure 2. Cytotoxicity of T. wormannii extract and isolates.
(A) HUVECs were plated at 106 cells/ml on goldfilm electrods in 96 well plates and allowed to attach and form a monolayer for 24 h before cells were treated with 1, 10 or 100 µg/ml crude extract or 20% DMSO (control) or left untreated and cell toxicity measured every 5 min for 24 h. (B) HeLa, CaCo-2, HaCaT, HUVEC and HKER cells were plated at 2×105 cells/ml in 96 well plates for 6 h and stimulated with 500 µg/ml–0.002 µg/ml crude extract for 24 h before Alamar blue was added (10%) and fluorescence intensity measured and the IC50 determined. (C) HUVECs were treated with 20 µg/ml or 200 µg/ml crude extract, with staurosporine (positive control) or left untreated (neg. control) for 24 h and apoptotic and necrotic cells measured using AnnexinV and 7-AAD. HaCaT (D), HUVEC (E) and HKER (F) were plated as described in B and cells stimulated with AA, BB, C and D.
Figure 3
Figure 3. Screening for anti-inflammatory T. wortmannii components.
(A) Flow cytometric analysis of ICAM-1 expression on the cell surface of HUVECs. Cells were stimulated with 10 ng/ml hTNF-α with or without 25 µg/ml crude extract or left untreated as negative control and stained with mouse anti-human ICAM-1 mAB. (B) Screening for anti-inflammatory substances, using a cell-based ELISA. Cells were treated for 1h in the absence or presence of 25 µg/ml substances AA, BB, C, D and crude extract, prior to being stimulated for 24 h with 10 ng/ml hTNF-α and stained with human ICAM-1 mAB (C) HEK293 cells were transiently transfected with NF-κB-Luciferase construct and EGFP construct. 24 h later, transfected cells were treated with 0, 40, 20 or 10 µg/ml substances or crude extract, prior to being stimulated with 10 ng/ml hTNF-α. Luciferase activities was determined 8 h later, normalized to the EFGP activities and expressed as fold increase over the control. (*, p<0.05; **, p<0.01, Students t test).
Figure 4
Figure 4. Effect of T. wortmannii substance C on P. acnes-induced activation of NF-
κB and AP1. HaCaT cells were transiently transfected with NF-κB- (A) or AP-1- Luciferase (B) as described in Fig. 3C and 24 h later treated with 0, 10, 20 or 40 µg/ml component C. After 2 h cells were then stimulated by incubation with P. acnes suspension and luciferase activities measured 8 h later. The data are the mean of three experiments +− standard deviation. (C) HaCaT cells were pre-treated with component C (Sub. C) for 2 h, and then stimulated with P. acnes suspension for 20 min. Phosphorylation and total protein expression of ERK, JNK, and IkB-α were detected by western blot analysis using specific antibodies. Tubulin was used as a loading control.
Figure 5
Figure 5. Effect of T. wortmannii components on P. acnes-induced IL-8 expression.
(A) HaCaT cells were pre-treated with 20 µg/ml components AA, BB, C, D, Crude extract or left untreated for 2 h and IL-8 production stimulated with P. acnes suspension for 24 h. Control experiments were run with cells alone (n.c.) or cells stimulated with P. acnes suspension (pos. contr.). (B) Pre-, co-, and post-treatment effects of several concentrations of component C on P. acnes–induced IL-8 expression in HaCaT cells. (C) HaCaT cells were stimulated with different P. acnes strains (P. acnes, P. acnes (ERYR), P. acnes_5-7) and post-treated with 20 µg/ml component C 3 h later. Data are presented as the mean+- standard deviation of three independent experiments. Statistical significance is indicated by *, p<0.05; **, p<0.01, Students t test.

Similar articles

Cited by

References

    1. White GM (1998) Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 39: S34–7. - PubMed
    1. Zouboulis CC, Eady A, Philpott M, Goldsmith LA, Orfanos C, et al. (2005) What is the pathogenesis of acne? Exp Dermatol 14(2): 143–52. - PubMed
    1. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, et al.. (2009) New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 60 (5 Suppl): :S1–50 - PubMed
    1. Koreck A, Pivarcsi A, Dobozy A, Kemény L (2003) The role of innate immunity in the pathogenesis of acne. Dermatology 206(2): 96–105. - PubMed
    1. Thiboutot D (2004) Regulation of human sebaceous glands. J Invest Dermatol 123(1): 1–12. - PubMed

Publication types

MeSH terms